VVT Med Signs Largest European Distribution Agreement to Date; Distributor Joins as Investor

Executive Summary of Latest Release

• VVT Med Inc. announced its largest European distribution agreement to date with Uber Ros S.p.A.
• The territory covers Italy, Vatican City, and San Marino for the exclusive commercialization of the ScleroSafe® system.
• The agreement is a five-year term signed April 9, 2026, with potential revenue of approximately CAD $2.3 million based on minimum purchase commitments.
• Uber Ros S.p.A. has joined the Company’s previously announced non-brokered private placement as an investor.
• CapitaLynx Ltd. (Arx) engaged for Investor Relations services at US$37,500 initial fee plus quarterly renewals.

Revenue Recognition and Cash Flow

• The CAD $2.3 million revenue potential is spread over five years, averaging roughly CAD $460,000 annually.
• This figure represents minimum purchase commitments rather than guaranteed sales; actual realization depends on physician adoption rates in the region.
• As this is a distribution agreement, VVT Med likely receives royalties or wholesale margins rather than full retail revenue, meaning the net impact to the bottom line will be lower than the headline $2.3 million suggests.

Corporate Profile

• VVT Med Inc. operates in the medical device sector focusing on vascular disease treatment solutions.
• The company is listed on the TSX Venture Exchange (TSXV: VVT).
• Management includes CEO Erez Tetro, who emphasizes international expansion as a core strategy.